Skip to content
DataLookout
Menu

NCT06174987

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Feb 17, 2028 Show 4 more changesShow less
    • Enrollment increased: 50 → 75 participants
    • Eligibility criteria expanded, about 187 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Trial sites expanded: 28 → 34 locations
  2. Minor Study completion date: Aug 3, 2026 to Jan 17, 2028v10
  3. Minor Study sites: 25 to 28v9
  4. Minor Site details revised at 1 of 25 sitesv8
  5. Minor Study sites: 24 to 25v7
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Site details revised at 1 of 24 sitesv6
  2. Minor Site details revised at 3 of 24 sitesv5
  3. Minor Site details revised at 5 of 24 sitesv4
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 27 to 24
    • Start date changed from estimate of Mar 31, 2024 to Jan 5, 2024
    v3
  5. Notable Start date: Dec 31, 2023 to Mar 31, 2024v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants Reporting Treatment-emergent Adverse Events Leading to Study Drug discontinuation and/or Dose Reduction, Treatment-emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (AESIs)
Timeframe: Baseline until disease progression, loss of clinical benefit, death, adverse event, pregnancy, withdrawal of consent, access to commercial supply, physician decision, or study closure, whichever occurs first, up to approximately 2 years 9 months

Arms and interventions

T-DXdExperimental

Participants who choose to continue treatment with T-DXd may be enrolled. Participants who were on the comparator arm in the parent study will be provided the option to access the drug through standard of care (SoC) or other available options. Participants will remain on their current dosage regimen of T-DXd as the last dose administered in the parent study, unless they experience an AE that requires dose reduction at the EOT of the parent study, in which case the starting dose in this study will be the next lower dose-level.

Drugs: T-DXd

Sites

34 sites in 13 countries

Turkey (Türkiye) 6, France 4, Brazil 3, China 3, Italy 3, South Korea 3, Spain 3, Japan 2, Taiwan 2, United States 2, Australia 1, Hong Kong 1, Israel 1